Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
91 hedge funds and large institutions have $154M invested in Poseida Therapeutics, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 23 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
43% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 23
43% more capital invested
Capital invested by funds: $108M → $154M (+$45.9M)
6% more funds holding
Funds holding: 86 → 91 (+5)
96% less call options, than puts
Call options by funds: $6K | Put options by funds: $156K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.37M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.13M |
| 3 |
Morgan Stanley
New York
|
+$1.04M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$672K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$605K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.05M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$902K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$663K |
| 4 |
Renaissance Technologies
New York
|
-$652K |
| 5 |
Squarepoint
New York
|
-$529K |
PSTX Hedge Fund Activity: Q4 2023 in Review
91 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q4 2023, worth a combined $154M — up 43% from $108M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PSTX positions and 10 closed out — a net gain of 6 holders — while 33 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $3.37M. The largest seller was Millennium Management, cutting an estimated $5.05M.
- 91 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q4 2023, up from 86 in Q3 2023.
- Funds reported $154M of Poseida Therapeutics, Inc. Common Stock stock for Q4 2023, up 43% quarter-over-quarter.
- 16 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q4 2023 and 10 closed out, a net change of +6 holders.
- The largest Poseida Therapeutics, Inc. Common Stock buyer in Q4 2023 was Fidelity Investments, an estimated $3.37M added.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q4 2023 was Millennium Management, an estimated $5.05M sold.
Based on aggregated 13F filings for Q4 2023.